Lipid screening in children and adolescents

JAMA - Journal of the American Medical Association

Volumn 316, Issue 6, 2016, Pages 589-591

  Urbina, Elaine M ^a   De Ferranti, Sarah D ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; LIPID;

ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; CHILD HEALTH CARE; CHILDHOOD OBESITY; CLINICAL DECISION MAKING; COHORT ANALYSIS; CORONARY ARTERY ATHEROSCLEROSIS; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; EDITORIAL; FAMILIAL HYPERCHOLESTEROLEMIA; FOLLOW UP; GENE; GENETIC VARIABILITY; HEALTH CARE POLICY; HEART INFARCTION; HUMAN; LIFESTYLE MODIFICATION; LOSS OF FUNCTION MUTATION; MASS SCREENING; MORBIDITY; MORTALITY; MULTIFACTORIAL DYSLIPIDEMIA; PCSK9 GENE; PHENYLKETONURIA; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; UNITED STATES; ADOLESCENT; ADVISORY COMMITTEE; AGE; BLOOD; CHILD; COMPLICATION; DYSLIPIDEMIAS; HYPERLIPOPROTEINEMIA TYPE II; INFANT; NEWBORN; PREVENTIVE HEALTH SERVICE; STANDARDS; YOUNG ADULT;

ADOLESCENT; ADVISORY COMMITTEES; AGE FACTORS; ATHEROSCLEROSIS; CAROTID INTIMA-MEDIA THICKNESS; CHILD; DYSLIPIDEMIAS; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; INFANT; INFANT, NEWBORN; LIPIDS; MASS SCREENING; PEDIATRIC OBESITY; PRACTICE GUIDELINES AS TOPIC; PREVENTIVE HEALTH SERVICES; UNITED STATES; YOUNG ADULT;

EID: 84981294030     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.9671     Document Type: Editorial

References (33)

1. US Preventive Services Task Force. Screening for lipid disorders in children and adolescents: US Preventive Services Task Force recommendation statement. JAMA. doi:10.1001/jama.2016.9852.
2. US Preventive Services Task Force. Screening for lipid disorders in children: US Preventive Services Task Force recommendation statement. Pediatrics. 2007;120(1):e215-e219.
3. Lozano P, Henrikson NB, Dunn J, et al. Lipid screening in childhood and adolescence for detection of familial hypercholesterolemia: evidence report and systematic review for the US Preventive Services Task Force. JAMA. doi:10.1001/jama.2016.6176.
4. Lozano P, Henrikson NB, Morrison CC, et al. Lipid screening in childhood and adolescence for detection of multifactorial dyslipidemia: evidence report and systematic review for the US Preventive Services Task Force. JAMA. doi:10.1001/jama.2016.6423.
5. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: summary report. Pediatrics. 2011;128(suppl 5):S213-S256.
6. Gidding SS, Champagne MA, de Ferranti SD, et al; American Heart Association Atherosclerosis, Hypertension, and Obesity in Young Committee of Council on Cardiovascular Disease in Young, Council on Cardiovascular and Stroke Nursing, Council on Functional Genomics and Translational Biology, and Council on Lifestyle and Cardiometabolic Health. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation. 2015;132(22):2167-2192.
7. Jacobson TA, Maki KC, Orringer CE, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2. J Clin Lipidol. 2015;9(6) (suppl):S1-S122.
8. de Ferranti SD, Rodday AM, Mendelson MM, Wong JB, Leslie LK, Sheldrick RC. Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES). Circulation. 2016;133(11):1067-1072.
9. Neil HA, Hammond T, Huxley R, Matthews DR, Humphries SE. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ. 2000;321(7254):148.
10. Braamskamp MJ, Kastelein JJ, Kusters DM, Hutten BA, Wiegman A. Statin initiation during childhood in patients with familial hypercholesterolemia: consequences for cardiovascular risk. J AmColl Cardiol. 2016;67(4):455-456.
11. Marcus MD, Baranowski T, De Bar LL, et al. Severe obesity and selected risk factors in a sixth grade multiracial cohort: the HEALTHY study. J Adolesc Health. 2010;47:604-607.
12. Robins SJ, Lyass A, Zachariah JP, Massaro JM, Vasan RS. Insulin resistance and the relationship of a dyslipidemia to coronary heart disease: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2011;31(5):1208-1214.
13. Lloyd-Jones DM, Hong Y, Labarthe D, et al; American Heart Association Strategic Planning Task Force and Statistics Committee. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic impact goal through 2020 and beyond. Circulation. 2010;121(4):586-613.
14. Oikonen M, Laitinen TT, Magnussen CG, et al. Ideal cardiovascular health in young adult populations from the United States, Finland, and Australia and its association with cIMT: the International Childhood Cardiovascular Cohort Consortium. J AmHeart Assoc. 2013;2(3):e000244.
15. Pahkala K, Hietalampi H, Laitinen TT, et al. Ideal cardiovascular health in adolescence: effect of lifestyle intervention and association with vascular intima-media thickness and elasticity (the Special Turku Coronary Risk Factor Intervention Project for Children [STRIP] study). Circulation. 2013;127(21):2088-2096.
16. Bacha F, Edmundowicz D, Sutton-Tyrell K, Lee S, Tfayli H, Arslanian SA. Coronary artery calcification in obese youth: what are the phenotypic and metabolic determinants? Diabetes Care. 2014;37(9):2632-2639.
17. Kusters DM, Avis HJ, de Groot E, et al. Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia. JAMA. 2014;312(10):1055-1057.
18. Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA. 2004;292(3):331-337.
19. Crouse JR III, Raichlen JS, Riley WA, et al; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA. 2007;297(12):1344-1353.
20. Baldassarre D, Veglia F, Hamsten A, et al; IMPROVE Study Group. Progression of carotid intima-media thickness as predictor of vascular events: results from the IMPROVE study. Arterioscler Thromb Vasc Biol. 2013;33(9):2273-2279.
21. Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a mendelian randomization analysis. J AmColl Cardiol. 2012;60(25):2631-2639.
22. Dwyer T, Sun C, Magnussen CG, et al. Cohort profile: the International Childhood Cardiovascular Cohort (i3C) consortium. Int J Epidemiol. 2013;42(1):86-96.
23. Wiegman A, Gidding SS, Watts GF, et al; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36):2425-2437.
24. Dixon DB, Kornblum AP, Steffen LM, Zhou X, Steinberger J. Implementation of lipid screening guidelines in children by primary pediatric providers. J Pediatr. 2014;164(3):572-576.
25. Ritchie SK, Murphy EC, Ice C, et al. Universal vs targeted blood cholesterol screening among youth: the CARDIAC Project. Pediatrics. 2010;126(2):260-265.
26. Goldberg AC, Gidding SS. Knowing the prevalence of familial hypercholesterolemia matters. Circulation. 2016;133(11):1054-1057.
27. Ademi Z, Watts GF, Pang J, et al. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. J Clin Lipidol. 2014;8(4):390-400.
28. Pratt RE, Kavey RE, Quinzi D. Combined dyslipidemia in obese children: response to a focused lifestyle approach. J Clin Lipidol. 2014;8(2):181-186.
29. Nechuta SJ, Shu XO, Yang G, et al. Adolescent exercise in association with mortality from all causes, cardiovascular disease, and cancer among middle-aged and older Chinese women. Cancer Epidemiol Biomarkers Prev. 2015;24(8):1270-1276.
30. Dennison BA. Bright futures and NHLBI integrated pediatric cardiovascular health guidelines. Pediatr Ann. 2012;41(1):e31-e36.
31. Zachariah JP, McNeal CJ, Copeland LA, et al. Temporal trends in lipid screening and therapy among youth from 2002 to 2012. J Clin Lipidol. 2015;9(5) (suppl):S77-S87.
32. McCrindle BW, Urbina EM, Dennison BA, et al; American Heart AssociationWriting Group. Summary of the American Heart Association's scientific statement on drug therapy of high-risk lipid abnormalities in children and adolescents. Arterioscler Thromb Vasc Biol. 2007;27(5):982-985.
33. Health Grades Inc. Prevalence and incidence of phenylketonuria. http://www.rightdiagnosis.com/p/phenylketonuria/prevalence.htm. Accessed July 18, 2016.